Metformin
Glucophage^®
500 mg - 850 mg
OD to TID
Maximum daily dose: 2550 mg
Covered
- Characteristics and clinical considerations

Metformin ER
Glumetza^®
500 mg - 1000 mg
OD
Maximum daily dose: 2000 mg
Not covered / Private coverage
- Characteristics and clinical considerations

Acarbose
Glucobay^TM
50 mg - 100 mg
OD to TID
Maximum daily dose: 300 mg
Covered
How to initiate
- Characteristics and clinical considerations

Alogliptin
Nesina^®
6.25 mg - 12.5 mg - 25 mg
OD
Code EN148-149-167
- Characteristics and clinical considerations

Alogliptin and Metformin
Kazano^TM
12.5 mg/500 mg - 12.5 mg/850 mg - 12.5 mg/1000 mg
BID
Code EN150
- Characteristics and clinical considerations

Linagliptin
Trajenta^®
5 mg
OD
Code EN148-167
- Characteristics and clinical considerations

Linagliptin and Metformin
Jentadueto^TM
2.5 mg/500 mg - 2.5 mg/850 mg - 2.5 mg/1000 mg
BID
Code EN150
- Characteristics and clinical considerations

Saxagliptin
Onglyza^®
2.5 mg - 5 mg
OD
Code EN148-149
- Characteristics and clinical considerations

Saxagliptin and Metformin
Komboglyze^®
2.5 mg/500 mg - 2.5 mg/850 mg - 2.5 mg/1000 mg
BID
Code EN150
- Characteristics and clinical considerations

Sitagliptin
Januvia^®
25 mg - 50 mg - 100 mg
OD
Code EN148-167
- Characteristics and clinical considerations

Sitagliptin and Metformin
Janumet^®
50 mg/500 mg - 50 mg/850 mg - 50 mg/1000 mg
BID
Code EN150
- Characteristics and clinical considerations

Sitagliptin and Metformin ER
Janumet^® XR
50 mg/500 mg - 50 mg/1000 mg - 100 mg/1000 mg
OD
Code EN150
- Characteristics and clinical considerations

Canaglifozin
Invokana^®
100 mg - 300 mg
OD
Code EN148-149-167
- Cardio-renal protection clinical data
- Characteristics and clinical considerations

Canaglifozin and Metformin
Invokamet^®
50 mg/500 mg - 50 mg/1000 mg - 150 mg/500 mg - 150 mg/1000 mg
BID
Not covered / Private coverage
- Cardio-renal protection clinical data
- Characteristics and clinical considerations

Dapagliflozin
Forxiga^®
5 mg - 10 mg
OD
Code EN148-149 - Code CV399
- Cardio-renal protection clinical data
- Characteristics and clinical considerations

Dapagliflozin and Metformin
Xigduo^®
5 mg/850 mg - 5 mg/1000 mg
BID
Code EN150
- Cardio-renal protection clinical data
- Characteristics and clinical considerations

Empagliflozin
Jardiance^®
10 mg - 25 mg
OD
Code EN148-167-179
- Cardio-renal protection clinical data
- Characteristics and clinical considerations

Empagliflozin and Linagliptin
Glyxambi^®
10 mg/ 5 mg - 25 mg/5 mg
OD
Not covered / Private coverage
- Cardio-renal protection clinical data
- Characteristics and clinical considerations

Empagliflozine and Metformin
Synjardy^TM
5 mg/500 mg - 5/850 mg - 5 mg/1000 mg - 12.5 mg/500 mg - 12.5 mg/850 mg - 12.5 mg/1000 mg
BID
Code EN219
- Cardio-renal protection clinical data
- Characteristics and clinical considerations

Gliclazide
Diamicron^®
80 mg
OD to BID
Maximum daily dose: 320 mg
Covered
- Characteristics and clinical considerations

Gliclazide Modified Release
Diamicron^®MR
30 mg - 60 mg
OD
Maximum daily dose: 120 mg
Covered
- Characteristics and clinical considerations

Glimepiride
Amaryl^®
1 mg - 2 mg - 4 mg
OD to BID
Maximum daily dose: 8 mg
Code EN23
- Characteristics and clinical considerations

Glyburide
Diabeta^®
2.5 mg - 5 mg
OD to BID
Maximum daily dose: 20 mg
Covered
- Characteristics and clinical considerations

Repaglinide
GlucoNorm^®
0.5 mg - 1 mg - 2 mg
OD to TID AC
Maximum daily dose: 16 mg
Covered
- Characteristics and clinical considerations

Pioglitazone
Actos^®
15 mg - 30 mg - 45 mg
OD
Code EN117-118-119-121
- Characteristics and clinical considerations

Rosiglitazone
Avandia^®
2 mg - 4 mg - 8 mg
OD
Code EN117-118-119-121
- Characteristics and clinical considerations

Dulaglutide
Trulicity^®
0.75 mg - 1.5 mg
(3.5 and 4.5 mg not yet available for purchase in Canada )
Once-Weekly
Stability at room temperature : 14 days
Private coverage orRAMQ (according to criteria) - Online Request Only
(Infolettre RAMQ)
Instructions for Use - Video
- Cardio-renal protection clinical data
- Characteristics and clinical considerations

Liraglutide
Victoza^®
0.6 mg - 1.2 mg - 1.8 mg
OD
Stability at room temperature : 30 days
Private coverage or RAMQ (according to criteria) - Online Request Only
(Infolettre RAMQ)
Video demo. of the injection technic
- Cardio-renal protection clinical data
- Characteristics and clinical considerations

Lixisenatide
Adlyxine^TM
10 ug/dose (0.05 mg/ml)
20 ug/dose (0.1 mg/ml)
OD
Stability at room temperature : 14 days
Not covered / Private coverage
- Cardio-renal protection clinical data
- Characteristics and clinical considerations

Tirzepatide
Mounjaro^MC
2.5 mg - 5 mg - 7.5 mg - 10 mg - 12.5 mg - 15 mg (0.5 ml per vial, single-dose vial)
Once-Weekly
Stability at room temperature : 21 days
Private coverage
- Complet Web Site
- Instruction for use
- Patient Brochure
- Injection Training Video

Semaglutide (s/c)
Ozempic^®
0.25 mg - 0.5 mg - 1 mg
(2 mg approved in Canada but not yet available for purchase)
Once-Weekly
Stability at room temperature : 8 weeks
Private coverage or RAMQ (according to criteria) - Online Request Only
(Infolettre RAMQ)
Video demo. of the injection technic (8 Languages)
- Cardio-renal protection clinical data
- Characteristics and clinical considerations
- Multilingual treatment guide
- Supply Difficulties (FR)

Semaglutide (s/c)
Wegovy^TM Obesity (≧ 30 BMI) et DB2 (≧ 27 BMI)
0.25 mg - 0.5 mg - 1 mg - 1.7 mg - 2.4 mg (Approved in Canada but not yet available for purchase)
Once-Weekly
Conservation : 8 weeks
Private coverage (when available)

Semaglutide (oral)
Rybelsus^®
3 mg - 7 mg - 14 mg
OD
Private coverage
- Patient Guide
- Getting Started
- Cardio-renal protection clinical data
- Characteristics and clinical considerations

Glargine U100 (100 units/ml) / Lixisenatide (33 mcg/ml)
Soliqua^TM
Maximum recommended daily dose is 60 units:
Glargine U100 60 units / Lixisenatide 20 mcg
Not Covered / Private coverage
How to Inject (video)
How to Inject (pdf)
Therapy Initiation and Titration
- Cardio-renal protection clinical data
- Characteristics and clinical considerations

Degludec (100 units/ml) / Liraglutide (3.6 mg/ml)
Xultophy^®
Maximum recommended daily dose is 50 units:
Degludec 50 units / Liraglutide 1.8 mg
Not Covered / Private coverage
Therapy Initiation and Titration
- Cardio-renal protection clinical data
- Characteristics and clinical considerations